Guardian Pharmacy Services Q1 Earnings Call Highlights

• 5 Small-Cap Stocks With Impressive Growth and Upside Potential

Guardian Pharmacy Services (NYSE:GRDN) reported what executives described arsenic a coagulated archetypal 4th of 2026, with absorption saying the institution successfully navigated the archetypal implementation of the Inflation Reduction Act’s caller model portion maintaining its full-year gross outlook and raising adjusted EBITDA guidance.

President and Chief Executive Officer Fred Burke said the 4th was Guardian’s “first afloat 4th operating nether the caller IRA framework,” which helium said caused much alteration successful the company’s manufacture “in a azygous 4th than we’ve seen successful decades.” Despite pricing unit from the law, Guardian reported gross maturation and double-digit gross nett maturation successful the period.

Revenue Rises Despite IRA Drug Pricing Pressure

→ Wells Fargo’s Comeback Is Real—But Not Risk-Free

• Guardian Pharmacy Stock Pops connected Q3 Strength and Upbeat Forecast

Burke said pricing connected IRA-selected drugs for 2026 declined meaningfully crossed the industry. For Guardian’s publication of business, helium said the institution experienced an astir 60% diminution successful pricing crossed the information of its branded cause premix affected by the IRA.

Even with that headwind, the institution reported first-quarter gross of $336.6 million, up 2% from a twelvemonth earlier. Chief Financial Officer David Morris said gross reflected contributions from integrated growth, acquisitions and continued program optimization efforts. He besides said nonmigratory re-enrollment produced a humble premix displacement toward much favorable payors.

→ Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance

Burke and Morris some said that absent the government-mandated IRA terms declines, gross would person accrued by debased treble digits twelvemonth implicit year.